

Peptide Array, Hepatitis C Virus, J4, E1 Protein

Catalog No. NR-3738

This reagent is the tangible property of the U.S. Government.

Product Description: The 28-peptide array spans the E1 protein of hepatitis C virus, J4 (genotype 1b; GenPept: AAC15722). Peptides are 16- to 18-mers, with 11 or 12 amino acid overlaps.

Lot: T5247-1 to T5247-28

The following information applies to all peptides:

- Appearance
- Mass spectral analysis
- Counter Ion

White lyophilized powder
Correct MW by MALDI-TOF
Trifluoroacetate

Peptide-specific information is shown in the two tables below.

Table 1							
Peptide	Date of Mfg.	Length	Sequence	Molecular Weight (amu)	Hydrophilicity	Purity by HPLC ^a	Peptide Content ^b
1 of 28	4/14/2011	18	1 YEVRNVSGIYHTNDCSN 18	2070.24	-0.61	96.8%	84.8%
2 of 28	4/14/2011	18	8 GIYHVTNDCSNSSIVYEA 25	1972.13	-0.09	88.1%	88.5%
3 of 28	4/14/2011	17	15 DCSNSSIVYEAADVIMH 31	1854.06	0.26	93.9%	89.1%
4 of 28	4/14/2011	16	21 IVYEAADVIMHTPGCV 36	1718.04	0.96	88.2%	87.3%
5 of 28	4/14/2011	18	26 ADVIMHTPGCVPCVQEGN 43	1870.17	0.22	91.8%	89.1%
6 of 28	4/14/2011	18	33 PGCVPCVQEGNSSRCWVA 50	1892.18	0.02	97.7%	88.1%
7 of 28	4/14/2011	18	39 VQEGNSSRCWVALTPLA 56	1932.2	0.07	95.6%	89.4%
8 of 28	4/14/2011	17	46 RCWVALTPLAARNASV 62	1829.17	0.5	94.3%	82.2%
9 of 28	4/14/2011	18	52 TPTLAARNASVPTTTIRR 69	1926.22	-0.37	99.8%	80.9%
10 of 28	4/14/2011	17	59 NASVPTTTIRRHVDLLV 75	1892.21	0.16	96.4%	81.5%
11 of 28	4/14/2011	16	65 TTIRRHVDLLVGTAAF 80	1770.08	0.54	97.3%	79.5%
12 of 28	4/14/2011	17	70 HVDLLVGTAAFCSAMYV 86	1797.14	1.35	93.9%	87.7%
13 of 28	4/14/2011	18	76 GTAAFCSAMYVGDLCGSI 93	1766.06	1.07	94.1%	88.6%
14 of 28	4/14/2011	18	83 AMYVGDLCGSIFLVSQLF 100	1963.36	1.41	95.3%	89.5%
15 of 28	4/14/2011	18	90 CGSIFLVSQLFTFSPRRH 107	2095.47	0.36	86.5%	82.1%
16 of 28	4/14/2011	18	97 SQLFTFSPRRHETVQDCN 114	2165.39	-1.01	94.8%	81.6%
17 of 28	4/14/2011	18	104 PRRHETVQDCNCNSIYPGH 121	2112.35	-1.23	94.4%	78.8%
18 of 28	4/14/2011	18	110 VQDCNCNSIYPGHVSGHRM 127	2003.28	-0.38	90.3%	81.6%
19 of 28	4/14/2011	17	117 IYPGHVSGHRMAWDMMM 133	2019.44	-0.1	88.6%	81.6%
20 of 28	4/14/2011	18	123 SGHRMAWDMMMNSPTTA 140	2110.46	-0.57	91.5%	85.2%
21 of 28	4/14/2011	18	130 DMMMNSPTTALVVSQLL 147	2037.46	0.63	88.2%	89.9%
22 of 28	4/14/2011	18	137 PTTALVVSQLLRIPQAVV 154	1905.33	1.08	85.3%	88.3%
23 of 28	4/14/2011	18	144 SLLRIPQAVVDMVAGAH 161	1905.27	0.61	94.5%	84.8%
24 of 28	4/14/2011	17	150 QAVVDMVAGAHWVLA 166	1721.03	0.95	95.3%	88.5%
25 of 28	4/14/2011	18	156 MVAGAHWVLAGLAYYSM 173	1897.26	1.02	85.4%	89.3%
26 of 28	4/14/2011	18	163 VLAGLAYYSMVGNWAKV 180	1899.26	0.81	87.6%	88.7%

Peptide	Date of Mfg.	Length	Sequence	Molecular Weight (amu)	Hydrophilicity	Purity by HPLC ^a	Peptide Content ^b
27 of 28	4/14/2011	18	170 YYSMVGNWAKVLIVALLF 187	2087.57	1.37	92.6%	90.4%
28 of 28	4/14/2011	16	177 WAKVLIVALLFAGVDG 192	1672.06	1.73	Crude	87.0%

^a% full-length
^bRemainder is salt and water

Peptide		Ala (A)	Arg (R)	Asx (N,D)	Cys (C)	Glx (Q,E)	Gly (G)	His (H)	Ile (I)	Leu (L)	Lys (K)	Met (M)	Phe (F)	Pro (P)	Ser (S)	Thr (T)	Trp (W)	Tyr (Y)	Val (V)
1 of 28	Expected		1.00	4.00	1.00	1.00	1.00	1.00	1.00						2.00	1.00		2.00	3.00
	Actual		1.00	4.00	0.58 ^a	0.99	1.11	0.89	0.80						1.95	0.95		2.10	3.00
2 of 28	Expected	1.00		3.00	1.00	1.00	1.00	1.00	2.00						3.00	1.00		2.00	2.00
	Actual	0.86		2.94	0.57 ^a	0.86	1.16	0.95	1.18 ^b						3.00	1.00		2.13	1.36 ^b
3 of 28	Expected	2.00		3.00	1.00	1.00		1.00	2.00			1.00			3.00			1.00	2.00
	Actual	1.87		2.75	0.53 ^a	0.93		1.10	0.90 ^b			0.98			2.90			1.00	0.88 ^b
4 of 28	Expected	2.00		1.00	1.00	1.00	1.00	1.00	2.00			1.00		1.00		1.00		1.00	3.00
	Actual	1.86		0.97	0.55 ^a	0.89	1.00	1.07	0.93 ^b			1.07		1.00		0.95		0.92	1.56 ^b
5 of 28	Expected	1.00		2.00	2.00	2.00	2.00	1.00	1.00			1.00		2.00		1.00			3.00
	Actual	0.98		2.00	1.09 ^a	2.15	1.84	1.06	0.62 ^b			0.80		2.00		0.95			1.49 ^b
6 of 28	Expected	1.00	1.00	1.00	3.00	2.00	2.00							2.00	2.00		1.00		3.00
	Actual	0.87	1.09	1.00	1.49 ^a	1.80	1.97							2.00	1.96		0.00 ^c		2.70
7 of 28	Expected	2.00	1.00	1.00	1.00	2.00	1.00			2.00				1.00	2.00	2.00	1.00		2.00
	Actual	2.00	1.09	1.00	0.52 ^a	1.80	1.10			1.87				1.15	2.02	1.91	0.00 ^c		1.98
8 of 28	Expected	4.00	2.00	1.00	1.00					2.00				1.00	1.00	2.00	1.00		2.00
	Actual	3.75	2.00	0.98	0.62 ^a					1.88				1.10	0.96	1.84	0.00 ^c		1.95
9 of 28	Expected	3.00	3.00	1.00					1.00	1.00				2.00	1.00	5.00			1.00
	Actual	3.09	2.96	0.99					0.80	0.95				2.00	1.00	4.81			1.05
10 of 28	Expected	1.00	2.00	2.00				1.00	1.00	2.00				1.00	1.00	3.00			3.00
	Actual	1.00	1.81	2.09				0.95	0.79	1.88				1.08	0.99	2.67			2.75
11 of 28	Expected	2.00	2.00	1.00			1.00	1.00	1.00	2.00			1.00			3.00			2.00
	Actual	2.15	1.81	1.09			1.10	1.00	0.76	1.96			1.13			2.91			2.05
12 of 28	Expected	3.00		1.00	1.00		1.00	1.00		2.00		1.00	1.00		1.00	1.00		1.00	3.00
	Actual	2.75		0.91	0.54 ^a		0.96	1.00		1.64		0.95	0.76		0.91	0.81		1.05	2.71
13 of 28	Expected	3.00		1.00	2.00		3.00		1.00	1.00		1.00	1.00		2.00	1.00		1.00	1.00
	Actual	3.00		1.10	0.82 ^a		2.98		0.98	1.10		1.19	0.86		1.99	0.86		0.98	1.10
14 of 28	Expected	1.00		1.00	1.00	1.00	2.00		1.00	3.00		1.00	2.00		2.00			1.00	2.00
	Actual	1.03		0.82	0.52 ^a	0.94	1.96		0.86	2.89		0.94	1.81		2.00			0.76	1.71
15 of 28	Expected		2.00		1.00	1.00	1.00	1.00	1.00	2.00			3.00	1.00	3.00	1.00			1.00
	Actual		2.00		0.48 ^a	0.80	0.94	1.04	0.81	1.66			2.67	1.06	2.69	1.00			0.88
16 of 28	Expected		2.00	2.00	1.00	3.00		1.00		1.00			2.00	1.00	2.00	2.00			1.00
	Actual		2.00	2.10	0.54 ^a	2.58		1.05		0.98			1.86	1.10	1.91	1.78			0.93
17 of 28	Expected		2.00	2.00	2.00	2.00	1.00	2.00	1.00					2.00	1.00	1.00		1.00	1.00
	Actual		2.10	2.07	1.13 ^a	1.99	1.02	2.00	0.75					2.10	0.99	0.91		0.80	0.90
18 of 28	Expected		1.00	2.00	2.00	1.00	2.00	2.00	1.00			1.00		1.00	2.00			1.00	2.00
	Actual		1.00	1.61	0.78 ^a	0.75	1.85	1.70	0.71			1.00		1.04	1.71			1.07	1.65

Table 2 - Amino Acid Analysis

Peptide		Ala (A)	Arg (R)	Asx (N,D)	Cys (C)	Glx (Q,E)	Gly (G)	His (H)	Ile (I)	Leu (L)	Lys (K)	Met (M)	Phe (F)	Pro (P)	Ser (S)	Thr (T)	Trp (W)	Tyr (Y)	Val (V)
19 of 28	Expected	1.00	1.00	1.00			2.00	2.00	1.00			4.00		1.00	1.00		1.00	1.00	1.00
	Actual	0.96	1.00	0.98			1.90	1.90	0.79			3.60		1.05	0.96		0.00 ^c	1.00	0.85
20 of 28	Expected	2.00	1.00	2.00			1.00	1.00				4.00		1.00	2.00	2.00	2.00		
	Actual	1.76	1.10	1.96			0.98	1.00				3.71		1.10	1.83	1.76	0.00 ^c		
21 of 28	Expected	1.00		2.00		1.00				3.00		3.00		1.00	2.00	2.00	1.00		2.00
	Actual	1.00		2.01		1.00				2.64		2.61		1.11	1.82	1.80	0.00 ^c		0.92 ^b
22 of 28	Expected	2.00	1.00			2.00			1.00	3.00				2.00	1.00	2.00			4.00
	Actual	2.00	0.94			1.93			0.96	2.75				2.08	1.03	1.82			2.59 ^b
23 of 28	Expected	3.00	1.00	1.00		2.00	1.00	1.00	1.00	2.00		1.00		1.00	1.00				3.00
	Actual	2.69	1.04	0.90		1.90	0.90	0.87	0.83	1.80		0.77		1.00	0.95				1.51 ^b
24 of 28	Expected	4.00		1.00		1.00	2.00	1.00		1.00		1.00		1.00			1.00		4.00
	Actual	3.76		1.02		0.95	1.87	0.97		0.76		0.98		1.00			0.00 ^c		2.57 ^b
25 of 28	Expected	4.00					3.00	1.00		2.00		2.00			1.00		1.00	2.00	2.00
	Actual	4.00					3.10	1.07		1.79		1.62			0.96		0.00 ^c	2.00	1.78
26 of 28	Expected	3.00		1.00			3.00			2.00	1.00	1.00			1.00		1.00	2.00	3.00
	Actual	3.00		1.03			3.00			1.70	0.86	0.76			1.05		0.00 ^c	2.10	2.70
27 of 28	Expected	2.00		1.00			1.00		1.00	3.00	1.00	1.00	1.00		1.00		1.00	2.00	3.00
	Actual	1.45		0.95			0.90		0.71 ^b	2.42	0.98	1.11	0.85		1.10		0.00 ^c	2.00	2.16 ^b
28 of 28	Expected	3.00		1.00			2.00		1.00	3.00	1.00			1.00			1.00		3.00
	Actual	2.67		0.85			2.00		0.68 ^b	2.60	0.85		1.04				0.00 ^c		2.15 ^b

^aCys was partially destroyed during hydrolysis

^bVal-Ile, Val-Val, Ile-Ile and/or Ile-Val bonds were only partially destroyed during hydrolysis

^cTrp was completely destroyed during hydrolysis

Date: 11 OCT 2011

Signature: *Dorothy C. Young*

Title: Technical Manager, BEI Authentication or designee

ATCC[®], on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected by the vendor to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC[®]'s knowledge.

ATCC[®] is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

